Lundbeck CEO considers stepping up marketing of Vyepti
The launch of migraine drug Vyepti has not gone well, meaning more will potentially be invested in the commercial apparatus behind the treatment.
By Josefine Buur Bach, translated by catherine brett
Migraine drug Vyepti was launched in the US in April 2020, and thanks to the Covid-19 crisis, this did not go well. CEO at Lundbeck Deborah Dunsire thinks the drug has the potential to become a blockbuster, but that requires a boost to the marketing of the drug, Danish financial daily Børsen reports.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
FDA approves Abbvie's preventative migraine tablet
For subscribers
Lundbeck silent on shutdown of Indian operations
For subscribers
.jpg)
.jpg&w=384&q=75)
